NAS sells off non-therapeutic product line
North American Scientific (NAS) has completed the sale of its non-therapeutic product line to the Berlin-based Eckert & Ziegler Isotope Products.
"We have successfully closed this transaction in the expected time frame and we are now focused on the therapeutic areas of our business with our Prospera and ClearPath product lines for local radiation treatment for the prostate and breast cancer patient," said John Rush, president and CEO of NAS.
"The proceeds from the sale of this product line will provide the company with important non-dilutive capital to invest in ongoing operations,” Rush said.
"We have successfully closed this transaction in the expected time frame and we are now focused on the therapeutic areas of our business with our Prospera and ClearPath product lines for local radiation treatment for the prostate and breast cancer patient," said John Rush, president and CEO of NAS.
"The proceeds from the sale of this product line will provide the company with important non-dilutive capital to invest in ongoing operations,” Rush said.